PT-141 (bremelanotide) is a melanocortin agonist studied for libido and erectile function. Learn how it works, dosing, nasal spray vs injection, and safety.
PT-141 is the research name for bremelanotide, a prescription medication that acts on melanocortin receptors in the brain to affect sexual desire and arousal. In the United States, bremelanotide is FDA-approved only as Vyleesi, a subcutaneous injection for premenopausal women with hypoactive sexual desire disorder (HSDD). It is not approved to treat erectile dysfunction in men, and it is not a cure for any sexual health condition.
What Is PT-141?
Bremelanotide belongs to a class of drugs called melanocortin receptor agonists. It began as a derivative of melanotan II, a compound researchers were studying for its effects on skin pigmentation. During those early trials, participants reported unexpected increases in sexual desire, and the research focus shifted.
The FDA approved bremelanotide in 2019 under the brand name Vyleesi. The main facts:
- Drug class: melanocortin receptor agonist, primarily active at the MC4 receptor.
- Approved brand: Vyleesi (bremelanotide injection), 1.75 mg.
- Approved use: hypoactive sexual desire disorder in premenopausal women.
- Approved route: subcutaneous injection into the abdomen or thigh.
- Half-life: roughly 2.7 hours.
- Research format: lyophilized powder sold online and reconstituted for injection or nasal use.
PT-141 itself is a research catalog name, not a brand name. Anything sold under that label is not FDA-approved.
How PT-141 Works
Bremelanotide activates melanocortin receptors in the hypothalamus, a brain region that helps regulate motivation and reward. That signaling appears to influence sexual desire centrally rather than by improving blood flow to the genitals.
That difference matters. PDE5 inhibitors like sildenafil work on vascular smooth muscle and mainly help with erection hardness. Bremelanotide is studied for desire and arousal, which is why researchers describe the two drug classes as acting through separate pathways.
Clinical trials in men did show some effect on erectile function, but the FDA did not approve bremelanotide for that use. Any male use is off-label or research-only.
PT-141 Nasal Spray vs Injection
The approved product is an injection. Most non-prescription interest, however, centers on the nasal route because it avoids needles. Compared with a subcutaneous injection, pt-141 nasal spray delivers the drug through the nasal lining and is not an FDA-approved product.
| Feature | Subcutaneous injection (Vyleesi) | Nasal spray (research use) |
|---|---|---|
| FDA status | Approved for HSDD in premenopausal women | Not approved |
| Typical dose | 1.75 mg | Often 7.5–10 mg in older studies |
| Onset | About 45 minutes or longer | Roughly 30–60 minutes |
| Dosing control | Fixed, pre-filled autoinjector | Variable; depends on mixing and sprayer |
| Notable issues | Injection site reactions, nausea | Blood pressure increases at higher doses; sterility and dosing accuracy concerns |
In clinical research, intranasal bremelanotide produced meaningful effects but also more blood pressure elevation than the injectable form, which is part of why the subcutaneous product moved forward. Anyone weighing pt-141 nasal spray vs injection should know that only the injection has gone through FDA review for safety, purity, and dosing.
Dosing and Timing
The FDA-approved pt-141 dosage for women is 1.75 mg injected under the skin of the abdomen or thigh, taken at least 45 minutes before anticipated sexual activity. The label limits use to one dose in 24 hours and no more than eight doses per month.
There is no approved dose for men. Research protocols circulating online vary widely, and doses used in early male trials do not map cleanly onto injected or nasal products sold today.
Many users ask how long does pt-141 last. Bremelanotide has a half-life of about 2.7 hours, and most reports describe noticeable effects for several hours after dosing, with side effects such as nausea often appearing first. The drug is not intended for daily use.
Because the onset is gradual, plan on waiting at least 45 minutes before effects begin. Taking a second dose soon after the first does not speed things up and raises the risk of nausea and blood pressure changes.
Prescriptions, Legality, and Access
Bremelanotide is a prescription-only medication in the United States. So, do you need a prescription for pt-141? Yes. Vyleesi is dispensed through a certified pharmacy, and some telehealth services can connect patients with a prescriber after a medical evaluation.
People searching for where to buy pt-141 often land on research chemical sites that sell vials labeled "not for human consumption." Those products are unregulated, may be under- or over-dosed, and can contain impurities or bacteria. Importing a prescription drug without a valid prescription is illegal in most circumstances.
Side Effects and Safety
The most common side effects reported in trials of the injectable form were nausea, flushing, headache, and injection site reactions. Nausea affected roughly 40% of participants, though most cases were mild.
More serious concerns include:
- Blood pressure and heart rate increases that appear shortly after dosing and can last for hours.
- Focal hyperpigmentation, including darkening of the gums, face, or other skin areas, with repeated use.
- Contraindication in people with uncontrolled high blood pressure or known cardiovascular disease.
Bremelanotide has not been studied in pregnancy, and it is not recommended for people who are breastfeeding. Anyone considering PT-141 should talk with a healthcare professional about their blood pressure, current medications, and cardiovascular history first.
Key Takeaways About PT-141
- PT-141 is the research name for bremelanotide, a melanocortin receptor agonist.
- Bremelanotide is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
- PT-141 nasal spray is not FDA-approved and is not a substitute for the injectable product.
- Bremelanotide has a half-life of about 2.7 hours, and reported effects typically fade within a few hours.
- Bremelanotide requires medical oversight, especially for people with heart or blood pressure conditions.
Frequently Asked Questions
Is PT-141 FDA-approved?
Bremelanotide, the drug known as PT-141, is FDA-approved as Vyleesi, a 1.75 mg subcutaneous injection for premenopausal women with hypoactive sexual desire disorder. Nasal sprays and research-grade powders sold under the PT-141 name are not FDA-approved. Bremelanotide is not approved to treat erectile dysfunction in men.
What are the side effects of PT-141?
Nausea is the most common side effect and affected about 40% of trial participants, followed by flushing, headache, and injection site reactions. Bremelanotide can also raise blood pressure and heart rate and may cause darkening of the skin or gums with repeated use. It is contraindicated in people with uncontrolled hypertension or known cardiovascular disease.
How long does PT-141 take to work?
Injected bremelanotide is usually taken at least 45 minutes before sexual activity, and many people notice effects within about an hour. The half-life is roughly 2.7 hours, and reported effects generally fade within a few hours. Doses should not be repeated within a 24-hour period.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.